{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005340","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.034025+00:00","generated_at":"2026-06-24T03:42:29.486872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin","bullets":["Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.","Adjusted operating income $3.1M vs $4.3M YoY; adjusted EPS $0.05 vs $0.06.","Gross margin improved to 58% from 57%.","Company discontinuing non-strategic products and cutting ~5% of global workforce.","FY2022 guidance: 1-5% reported revenue growth; adjusted operating margin 13-14%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005340","json":"https://secwatch.observer/filing/0001171843-22-005340.json","markdown":"https://secwatch.observer/filing/0001171843-22-005340.md","text":"https://secwatch.observer/filing/0001171843-22-005340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/0001171843-22-005340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184322005340/f8k_080422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:42:29.486872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}